Quimioterapia intra-arterial para el tratamiento del retinoblastoma: Experiencia de 8 años (2013 – 2020) en Clínica Foscal – Foscal Internacional

dc.contributorMantilla García, Daniel Eduardo
dc.contributorOchoa Vera, Miguel Enrique
dc.contributorMantilla García, Daniel Eduardo [0001437130]
dc.contributorOchoa Vera, Miguel Enrique [0000898465]
dc.contributorMantilla García, Daniel Eduardo [PUqdPK8AAAAJ]
dc.contributorOchoa Vera, Miguel Enrique [0000-0002-4552-3388]
dc.contributorMantilla García, Daniel Eduardo [6641574500]
dc.contributorOchoa Vera, Miguel Enrique [36987156500]
dc.contributorOchoa Vera, Miguel Enrique [Miguel-Ochoa-6]
dc.creatorRueda Badillo, Edward Yesid
dc.date.accessioned2022-03-25T19:13:50Z
dc.date.accessioned2023-06-12T20:15:45Z
dc.date.available2022-03-25T19:13:50Z
dc.date.available2023-06-12T20:15:45Z
dc.date.created2022-03-25T19:13:50Z
dc.date.issued2022
dc.identifierhttp://hdl.handle.net/20.500.12749/16058
dc.identifierinstname:Universidad Autónoma de Bucaramanga - UNAB
dc.identifierreponame:Repositorio Institucional UNAB
dc.identifierrepourl:https://repository.unab.edu.co
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/6661976
dc.description.abstractObjetivo: Evaluar la eficacia y seguridad del tratamiento con quimioterapia intraarterial a través de la arteria oftálmica en pacientes con retinoblastoma en FOSCAL- FOSCAL INTERNACIONAL en el periodo 2013-2020. Justificación: La quimioterapia intraarterial cambió la estrategia de tratamiento para el retinoblastoma, proporciona una alta tasa de éxito para salvar el globo ocular y controlar el tumor. Con el fin de ampliar el conocimiento sobre la factibilidad de este sofisticado procedimiento en un país de ingresos medios como el nuestro, queremos presentar nuestra experiencia en pacientes del noreste de Colombia con retinoblastoma intraocular manejados con quimioterapia intraarterial supraselectiva. Tipo de estudio: Se trata de un estudio descriptivo de cohortes basado en datos secundarios. Población: Se incluirán todos los pacientes elegibles con diagnóstico de retinoblastoma desde el 1 de enero de 2013 hasta el 1 de septiembre de 2020 sometidos a quimioterapia intraarterial selectiva a través de la arteria oftálmica en FOSCAL- FOSCAL INTERNACIONAL, será un estudio censal. Resultados: Al evaluar el total de ojos de los 10 niños afectados por retinoblastoma fue del 65% (13/20 ojos), de los cuales 11 fueron tratados con quimioembolización. Se realizó la categorización de estadios según la clasificación internacional de retinoblastoma, observándose que de los 11 ojos llevados al QIA, el 63,64% (n=7) eran categoría D, seguido de la categoría E 27,27% (n=3) y la categoría C 9,09% (n=1). Al evaluar la supervivencia global, ningún paciente falleció y la mediana de seguimiento fue de 53 meses. La supervivencia media libre de enucleación fue de 23 meses, la primera enucleación de los 11 ojos después de la quimioembolización fue a los 6 meses. Conclusiones: La quimioterapia intraarterial es una modalidad potente, segura y eficaz que puede reducir la tasa de enucleación en pacientes con retinoblastoma. Se observó mejor respuesta en el grupo C; sin embargo, sería ideal definir el riesgo/beneficio de dicho tratamiento para un mayor número de pacientes en etapas tempranas. Todos los pacientes del grupo E acabaron en enucleación, lo que refuerza los hallazgos de los diferentes estudios en los que la eficacia en estadios avanzados es baja y se prefiere la enucleación.
dc.languagespa
dc.publisherUniversidad Autónoma de Bucaramanga UNAB
dc.publisherFacultad Ciencias de la Salud
dc.publisherEspecialización en Radiología e Imágenes Diagnósticas
dc.relation1. Suzuki S, Yamane T, Mohri M, Kaneko A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011;118(10):2081-
dc.relation2. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115(8):13981404.e1
dc.relation3. Chawla B.(2020) Retinoblastoma: Diagnosis, Classification and Management. In: Khetan V. (eds) Intraocular Tumors. Springer, Singapore
dc.relation4. Li B., Zhang X. (2020) A Review of Retinoblastoma from the Perspective of Integrative Medicine. In: Wang N. (eds) Integrative Ophthalmology. Advances in Visual Science and Eye Diseases, vol 3. Springer, Singapore
dc.relation5. Abramson DH. Retinoblastoma in the 20th century: past success and future challenges the Weisenfeld lecture. Invest Ophthalmol Vis Sci. 2005;46(8):2683-2691
dc.relation6. Enrique MachíRetinoblastoma: a molecular, clinical and therapeutic approach. Archivos Venezolanos de Farmacología y Terapéutica, vol. 36, núm. 5, 2017, pp. 115-131
dc.relation7. Qian J. Some problems should be paid attention to in the treatment of retinoblastoma. Ophthalmology. 2009;18(6):367–9
dc.relation8. Wippold FJ, 2nd, Perry A. Neuropathology for the neuroradiologist: rosettes and pseudorosettes. AJNR Am J Neuroradiol. 2006;27(3):488–492.
dc.relation9. Mendoza PR, Specht CS, Hubbard GB, Wells JR, Lynn MJ, Zhang Q, Kong J, Grossniklaus HE. Histopathologic grading of anaplasia in retinoblastoma. Am J Ophthalmol. 2015;159(4):764–776
dc.relation10. Finger PT. The 7th Edition AJCC Staging System for Eye Cancer an international language for ophthalmic oncology. Arch Pathol Lab Med. 2009;133(8):1197–1198
dc.relation11. Gallie BL, Mallipatna A, Finger P, Zhao J, Kivela T, Chantada G, Lau W, Ramirez-Ortiz MA, Catala J, Yousef Y, Ushakova T, Yarovoy A, Wilson M, Khetan V, Walsh J, Blair P, Renner L, Teekappanava N. International survey of staging for retinoblastoma provides evidence for the 2016 8th Edition AJCC TNMH retinoblastoma cancer staging. Pediatr Blood Cancer. 2016;63:S21– S21
dc.relation12. Mallipatna AC, Gallie BL, Chevez-Barrios P, Lumbroso-Le Rouic L, Chantada GL, Brisse HJ, Doz F, Munier FL, Albert DM, Català-Mora J, Desjardins LG, Suzuki S, Carroll WL, Coupland SE, Finger PT. Retinoblastoma. In: Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC Cancer Staging Manual. 8. New York: Springer International Publishing; 2017
dc.relation13. Bin Li and Xiao Zhang A Review of Retinoblastoma from the Perspective of Integrative Medicine
dc.relation14. Chawla B., Seth R., Moksha L. (2016) Chemotherapy for Ocular Cancers. In: Velpandian T. (eds) Pharmacology of Ocular Therapeutics. Adis, Cham
dc.relation15. Rao R, Honavar SG. Retinoblastoma. Indian Journal of Pediatrics. 2017 Dec;84(12):937-944
dc.relation16. Novotný A, Krásný J. K diagnostice retinoblastomu ultrazvukem [Diagnosis of retinoblastoma using ultrasound]. Cas Lek Cesk. 1990;129(12):364-365.
dc.relation17. Moulin AP, Gaillard MC, Balmer A, Munier FL. Ultrasound biomicroscopy evaluation of anterior extension in retinoblastoma: a clinicopathological study. Br J Ophthalmol. 2012;96(3):337-340
dc.relation18. Vasquez LM, Giuliari GP, Halliday W, Pavlin CJ, Gallie BL, Héon E. Ultrasound biomicroscopy in the management of retinoblastoma. Eye (Lond). 2011;25(2):141-147
dc.relation19. Rootman DB, Gonzalez E, Mallipatna A, Vandenhoven C, Hampton L, Dimaras H, et al. Hand-held high-resolution spectral domain optical coherence tomography in retinoblastoma: clinical and morphologic considerations. Br J Ophthalmol. 2013;97:59–65
dc.relation20. Chawla B, Sharma S, Sen S, Azad R, Bajaj MS, Kashyap S, etal. Correlation between clinical features, MRI and histopathologic ‑ndings in retinoblastoma: a prospective study. Ophthalmology. 2012;119:850–6.
dc.relation21. de Jong MC, de Graaf P, Noij DP, Göricke S, Maeder P, Galluzzi P, etal. Diagnostic performance of magnetic resonance imaging and computed tomography for advanced retinoblastoma: a systematic review and metaanalysis. Ophthalmology. 2014;121:1109–18
dc.relation22. Razek AA, Elkhamary S. MRI of retinoblastoma. Br J Radiol. 2011;84(1005):775–784
dc.relation23. Galluzzi P, Hadjistilianou T, Cerase A, De Francesco S, Toti P, Venturi C. Is CT still useful in the study protocol of retinoblastoma? AJNR Am J Neuroradiol. 2009;30(9):1760–1765
dc.relation24. Chawla B, Duraipandi K, Sharma S.MRI in retinoblastoma associated orbital cellulitis. Ophthalmology. 2013;120:1308–9
dc.relation25. Reese AB, Ellsworth RM. The evaluation and current concept of retinoblastoma therapy. Trans Am Acad Ophthalmol Otolaryngol. 1963;67:164–72
dc.relation26. Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin N Am. 2005;18:41–53
dc.relation27. Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113:2276–80
dc.relation28. Michalinos A, Zogana S, Kotsiomitis E, Mazarakis A, Troupis T. Anatomy of the Ophthalmic Artery: A Review concerning Its Modern Surgical and Clinical Applications. Anat Res Int. 2015;2015:591
dc.relation29. Perrini P, Cardia A, Fraser K, Lanzino G. A microsurgical study of the anatomy and course of the ophthalmic artery and its possibly dangerous anastomoses. J Neurosurg. 2007;106(1):142-150
dc.relation30. Picard L., Vignaud J., Lombardi G., Roland J. Radiological anatomy of the origin of the ophthalmic artery. Modern Problems in Ophthalmology. 1975;14:164–169
dc.relation31. Hassler W., Zentner J., Voigt K. Abnormal origin of the ophthalmic artery from the anterior cerebral artery: neuroradiological and intraoperative findings. Neuroradiology. 1989;31(1):85–87
dc.relation32. Islak C., Ogüt G., Numan F., Cokyuksel O., Kuday C. Persistent nonmigrated ventral primitive ophthalmic artery. Report on one case. Journal of Neuroradiology. 1994;21(1):46–49.
dc.relation33. Hannequin P., Peltier J., Destrieux C., Velut S., Havet E., Le Gars D. The inter-optic course of a unique precommunicating anterior cerebral artery with aberrant origin of an ophthalmic artery: an anatomic case report. Surgical and Radiologic Anatomy. 2013;35(3):269–271. doi: 10.1007/s00276-012-10286
dc.relation34. Li Y., Horiuchi T., Yako T., Ishizaka S., Hongo K. Anomalous origin of the ophthalmic artery from the anterior cerebral artery. Neurologia MedicoChirurgica. 2011;51(8):579–5
dc.relation35. Huynh-Le P., Natori Y., Sasaki T. Surgical anatomy of the ophthalmic artery: Its origin and proximal course. Neurosurgery. 2005;57(supplement 4):236– 241. Hayreh S. S. Orbital vascular anatomy. Eye. 2006;20(10):1130–1144.
dc.relation36. Manjandavida, F. P., Stathopoulos, C., Zhang, J., Honavar, S. G., & Shields, C. L. (2019). Intra-arterial chemotherapy in retinoblastoma - A paradigm change. Indian journal of ophthalmology, 67(6), 740–7
dc.relation37. Gobin, Y.P., et al., Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 129(6): p. 732-7.
dc.relation38. Shields, C.L., et al., Intra-arterial Chemotherapy for Retinoblastoma: Report No. 2, Treatment Complications. Arch Ophthalmol. 129(11): p. 1407-15
dc.relation39. Abramson, D.H., Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol. 129(11): p. 1492-4. Shields, C.L., et al., Intra-arterial Chemotherapy for Retinoblastoma: Report No. 2, Treatment Complications. Arch Ophthalmol. 129(11): p. 1407-15
dc.relation40. Abramson, D.H., Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol. 129(11): p. 1492-4
dc.relation41. Brodie, S.E., et al., Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Doc Ophthalmol, 2009. 119(1): p. 13-22
dc.relation42. Munier, F.L., et al., Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina. 2011; 31(3): p. 566-7
dc.relation43. Vijayakrishnan, R., et al., Irradiation toxic effects during intra-arterial chemotherapy for retinoblastoma: should we be concerned? Arch Ophthalmol. 128(11): p. 1427-31
dc.relation44. Suzuki, S., et al., Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 118(10): p. 2081-7
dc.relation45. Peterson EC, Elhammady MS, Quintero-Wolfe S, Murray TG, Aziz-Sultan MA. Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: Initial experience with 17 tumors. J Neurosurg 2011;114:1603-8
dc.relation46. Muen WJ, Kingston JE, Robertson F, Brew S, Sagoo MS, Reddy MA. Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma. Ophthalmology 2012;119:611-6.
dc.relation47. Thampi S, Hetts SW, Cooke DL, Stewart PJ, Robbins E, Banerjee A, et al. Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: Results from a single institution. Clin Ophthalmol 2013;7:981-9
dc.relation48. Venturi C, Bracco S, Cerase A, Cioni S, Galluzzi P, Gennari P, et al. Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: Preliminary results from 140 treatments. Acta Ophthalmol 2013;91:335-42
dc.relation49. Shields CL, Manjandavida FP, Lally SE, Pieretti G, Arepalli SA, Caywood EH, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: Outcomes based on the international classification of retinoblastoma. Ophthalmology 2014;121:1453-6
dc.relation50. Taich P, Ceciliano A, Buitrago E, Sampor C, Fandino A, Villasante F, et al. Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma. Ophthalmology 2014;121:88997
dc.relation51. Parareda A, Català J, Carcaboso AM, Sola T, Cruz O, Díaz J, et al. Intraarterial chemotherapy for retinoblastoma. Challenges of a prospective study. Acta Ophthalmol 2014;92:209-15
dc.relation52. Ghassemi F, Ghanaati H, Karkhaneh R, Boujabadi L, Tabatabaie SZ, Rajabi MT. Outcome of retinoblastoma following limited sessions of intra-arterial chemotherapy in Iran. Iran J Radiol 2014;11:e16958
dc.relation53. Ong SJ, Chao AN, Wong HF, Liou KL, Kao LY. Selective ophthalmic arterial injection of melphalan for intraocular retinoblastoma: A 4-year review. Jpn J Ophthalmol 2015;59:109-17
dc.relation54. Akyüz C, Kıratlı H, Şen H, Aydın B, Tarlan B, Varan A. Intra-arterial chemotherapy for retinoblastoma: A single-center experience. Ophthalmologica 2015;234:227-32
dc.relation55. Abramson DH, Marr BP, Francis JH, Dunkel IJ, Fabius AW, Brodie SE, et al. Simultaneous bilateral ophthalmic artery chemosurgery for bilateral retinoblastoma (tandem therapy). PLoS One 2016;11:e0156806.
dc.relation56. Tuncer S, Sencer S, Kebudi R, Tanyıldız B, Cebeci Z, Aydın K. Superselective intra-arterial chemotherapy in the primary management of advanced intra-ocular retinoblastoma:First 4-year experience from a single institution in Turkey. Acta Ophthalmol 2016;94:e644-51.
dc.relation57. Michaels ST, Abruzzo TA, Augsburger JJ, Corrêa ZM, Lane A, Geller JI. Selective ophthalmic artery infusion chemotherapy for advanced intraocular retinoblastoma: CCHMC early experience. J Pediatr Hematol Oncol 2016;38:65-9
dc.relation58. Leal-Leal CA, Asencio-López L, Higuera-Calleja J, Bernal-Moreno M, BoschCanto V, Chávez-Pacheco J, et al. Globe salvage with intra arterial topotecan-melphalan chemotherapy in children with a single eye. Rev Invest Clin 2016;68:137-42
dc.relation59. Reddy MA, Naeem Z, Duncan C, Robertson F, Herod J, Rennie A, et al. Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma. Br J Ophthalmol 2017;101:1704-8
dc.relation60. Chen M, Jiang H, Zhang J, Shen G, Jiang Y, Li H, Liu Z. Outcome of intraarterial chemotherapy for retinoblastoma and its influencing factors: A retrospective study. Acta Ophthalmol 2017;95:613-8
dc.relation61. Rishi P, Sharma T, Sharma M, Maitray A, Dhami A, Aggarwal V, et al. Intraarterial chemotherapy for retinoblastoma: Two-year results from tertiary eyecare center in India. Indian J Ophthalmol 2017;65:311-5
dc.relation62. Ammanuel S, Alexander MD, Damato B, Cooke DL, Halbach VV, Amans MR, et al. Improved procedural safety following protocol changes for selective ophthalmic arterial infusion of chemotherapy for treatment of ocular retinoblastoma. Interv Neuroradiol 2018;24:345-50.
dc.relation63. Hua J, Gang S, Yizhou J, Jing Z. Intra-arterial chemotherapy as second-line treatment for advanced retinoblastoma: A 2-year single-center study in China. J Cancer Res Ther 2018;14:106-110
dc.relation64. Radros J, All-Eriksson C, Pal N, Holm S, Seregard S, Söderman M, et al. Intra-arterial chemotherapy for retinoblastoma in Sweden – Evaluation of treatment efficacy and complications. Acta Ophthalmol 2018;96:e1040-1
dc.relation65. Rojanaporn D, Chanthanaphak E, Boonyaopas R, Sujirakul T, Hongeng S, Ayudhaya SSN. Intra-arterial chemotherapy for retinoblastoma: 8-year experience from a tertiary referral institute in Thailand. Asia Pac J Ophthalmol (Phila) 2019. doi: 10.22608/APO.2018294.
dc.relation66. Instituto Nacional De Cancerologia de Colombia. Anuario Estad.stico. 2010:18
dc.relation67. CL Shields, EM Fulco, JD Arias. Retinoblastoma frontiers with intravenous, intraarterial, periocular, and intravitreal chemotherapy. Eye (2012), 1–12.
dc.relation68. www.salud.gob.sv › boletines epidemiológicos 2019
dc.relation69. Global Retinoblastoma Study Group, Fabian ID, Abdallah E, et al. Global Retinoblastoma Presentation and Analysis by National Income Level [published online ahead of print, 2020 Feb 27]. JAMA Oncol. 2020;6(5):1-12
dc.relation70. Bravo LE, García LS, Collazos P, Carrascal E, Ramírez O, Cortés A, Nuñez M, Millán E . I. Reliable data for cancer control in Cali, Colombia. Colomb Med (Cali). 2018; 49(1): 23-34.
dc.relation71. Abramson DH, Fabius AWM, Issa R, Francis JH, Marr BP, Dunkel IJ, et al. (2015) Advanced Unilateral Retinoblastoma: The Impact of Ophthalmic Artery Chemosurgery on Enucleation Rate and Patient Survival at MSKCC. PLoS ONE 10(12): e0145436
dc.relation72. Area C, Yen CJ, Chevez-Barrios P, Herzog C, Kan P, Zheng W, Lin F, Chintagumpala M, Gombos D, Chen SR. Technical and anatomical factors affecting intra-arterial chemotherapy fluoroscopy time and radiation dose for intraocular retinoblastoma. J Neurointerv Surg. 2019 Dec;11(12):1273-1276
dc.relation73. Shields CL, Shields JA. Editorial: chemotherapy for retinoblastoma. Med Pediatr Oncol. Jun 2002;38(6):377-378
dc.relation74. Harbour JW. What is the best treatment for retinoblastoma? Am J Ophthalmol. Sep 2004;138(3):471-473.Chantada GL, Fandino AC, Raslawski 76 EC, et al. Experience with chemoreduction and focal therapy for intraocular retinoblastoma in a developing country. Pediatr Blood Cancer. 2005;44(5):455-460.
dc.relation75. Shields CL, De Potter P, Himelstein BP, Shields JA, Meadows AT, Maris JM. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114(11):1330-1338.
dc.relation76. Shields JA, Shields CL, Meadows AT. Chemoreduction in the management of retinoblastoma. Am JOphthalmol. 2005;140(3):505-50
dc.relation77. Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial Chemotherapy for Retinoblastoma: Report No. 2, Treatment Complications. Arch Ophthalmol. 2011
dc.relation78. Abramson DH. Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol.2011;129(11):1492-1494
dc.relation79. Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011;129(6):732-737
dc.relation80. Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intra-arterial Chemotherapy for the Management of Retinoblastoma: Four-Year Experience. Arch Ophthalmol. 20
dc.relation81. Abramson DH, Shields CL, Munier FL, Chantada GL. Treatment of Retinoblastoma in 2015:Agreement and Disagreement. JAMA Ophthalmol. 2015;133(11):1341-13
dc.relation82. Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial Chemotherapy for Retinoblastoma:Report No.1, Control of Retinal Tumors, Subretinal Seeds, and Vitreous Seeds. Arch Ophthalmol.2
dc.relation83. Reese AB, Hyman GA, Merriam GR, Jr., Forrest AW, Kligerman MM. Treatment of retinoblastoma by radiation and triethylenemelamine. AMA Arch Ophthalmol. 1954;53(4):505-513.
dc.relation84. Kaneko A, Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn JClin Oncol. 2003;33(12):601-607
dc.relation85. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients With intraocular retinoblastoma. Int J Clin Oncol. 2004;9(2):69-73
dc.relation86. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial(ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results.Ophthalmology. 2008;115(8):13981404, 1404 e1391
dc.relation87. Shields CL, Manjandavida FP, Lally SE, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014;121(7):1453–60.
dc.relation88. Marr BP, Brodie SE, Dunkel IJ, Gobin YP, Abramson DH. Threedrug intraarterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results. Br J Ophthalmol. 2012;96(10):1300–3.
dc.relation89. Buitrago E, Del Sole MJ, Torbidoni A, et al. Ocular and systemic toxicity of intravitreal topotecan inrabbits for potential treatment of retinoblastoma. Exp Eye Res. 2013;108:103-109.
dc.relation90. Bogan CM, Kaczmarek JV, Pierce JM, et al. Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study. Br J Ophthalmol. 2021
dc.relation91. Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012;130(10):12681271
dc.relation92. .Shields CL, Kaliki S, Rojanaporn D, Al-Dahmash S, Bianciotto CG, Shields JA. Intravenous and intraarterial chemotherapy for retinoblastoma: what have we learned? Curr Opin Ophthalmol. 2012;23(3):202209.
dc.relation93. Dalvin, L. A., Kumari, M., Essuman, V. A., Shohelly Shipa, S., AnconaLezama, D., Lucio-Alvarez, J. A., Jabbour, P., & Shields, C. L. (2019). Primary Intra-Arterial Chemotherapy for Retinoblastoma in the Intravitreal Chemotherapy Era: Five Years of Experience. Ocular oncology and pathology, 5(2), 139–146.
dc.relation94. González M.E, López M, Enucleation Free Survival of Patients with Retinoblastoma Diagnosis Treated with Intraarterial Chemotherapy at University-Based San Vicente Fundacion Hospital.Rev. Sociedad Colombiana de Oftalmología Vol. 47 (2): 161 - 169, 2014
dc.relation95. Ravindran K, Dalvin LA, Pulido JS, Brinjikji W. Intra-arterialchemotherapy for retinoblastoma: An updated systematicreview and meta-analysis. J Neurointerv Surg.2019;11:1266–72,http://dx.doi.org/10.1136/neurintsurg2019-014909.2
dc.relation96. Yousef YA, Soliman SE, Astudillo PPP, Durairaj P, Dimaras H,Chan HSL, et al. Intra-arterial chemotherapy forretinoblastoma: A systematic review. JAMA Ophthalmol.2016;134:58491
dc.relation97. González ME, Gaviria ML, López M, Escudero PA, Bravo A, Vargas SA. Eye Salvage with Intra-Arterial and Intra-Vitreal Chemotherapy in Patients with Retinoblastoma: 8-Year Single-Institution Experience in Colombia. Ocul Oncol Pathol. 2021 Jun;7(3):215-223. doi: 10.1159/000511980
dc.relation98. Rojanaporn D, Chanthanaphak E, Boonyaopas R, Sujirakul T,Hongeng S, Ayudhaya SSN. Intra-arterial chemotherapy forretinoblastoma: 8-year experience from a tertiary referralinstitute in Thailand. Asia Pac J Ophthalmol (Phila).2019;8:211–7.
dc.relation99. Funes S, Sampor C, Villasante F, Fandi–o A, Manzitti J, Sgroi M, Neira P, Peralta L, Lagomarsino E, Schaiquevich P, Ceciliano A, Chantada GL. Feasibility and results of an intraarterial chemotherapy program for the conservative treatment of retinoblastoma in Argentina. Pediatr Blood Cancer. 2018 Aug;65(8):e27086. doi: 10.1002/pbc.27086
dc.relation100. Ting, S. C., Kiefer, T., Ehlert, K., Goericke, S. L., Hinze, R., Ketteler, P., Bechrakis, N. E., & Schildhaus, H. U. (2020). Bone metastasis of retinoblastoma five years after primary treatment. American journal of ophthalmology case reports, 19, 100834
dc.relation101. Roncallo Kelsey LG, Detection of Extraocular Lesions in A Patient with Bilateral Retinoblastoma Using 18F-FDG PET/CT.Biomedical Journal of Scientific & Technical Research April, 2019, Volume 17, 2, pp 12632-12634
dc.relation102. Kaewkhaw, R. y Rojanaporn, D. (2020). Retinoblastoma: etiología, modelado y tratamiento. Cánceres , 12 (8), 2304. https://doi.org/10.3390/cancers1208
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rightsAbierto (Texto Completo)
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.titleQuimioterapia intra-arterial para el tratamiento del retinoblastoma: Experiencia de 8 años (2013 – 2020) en Clínica Foscal – Foscal Internacional


Este ítem pertenece a la siguiente institución